Syros Pharmaceuticals Inc. closed its public offering, for net proceeds of about $37.3 million.
The company also closed a concurrent private placement of 125,656 common shares to Incyte Corp., raising proceeds of about $1.2 million.
Syros said its existing cash and the net proceeds from the offering and private placement will be enough to fund operations into 2020.
Cambridge, Mass.-based Syros develops treatments for cancer and immune-mediated diseases.
